Related Experiment Video

Updated: Jul 25, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets

Francesco Piccirillo1,2, Sara Mastroberardino1,2, Annunziata Nusca1,2

  • 1Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, Italy.

International Journal of Molecular Sciences
|June 28, 2023
PubMed

Insights

Novel antidiabetic drugs like SGLT2 inhibitors, DPP4 inhibitors, and GLP-1 RAs improve cardiovascular outcomes in type-2 diabetes. These agents also positively impact diabetic dyslipidemia, reducing cardiovascular risk.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Background:

  • Type-2 diabetes mellitus (DM) is a major risk factor for cardiovascular diseases (CVD).
  • Diabetic dyslipidemia, characterized by abnormal lipid profiles, exacerbates atherosclerosis and increases cardiovascular morbidity/mortality.
  • Traditional glycemic control alone may not fully address cardiovascular risk in diabetic patients.

Purpose of the Study:

  • To review the effects of novel antidiabetic agents on diabetic dyslipidemia.
  • To explore how these agents contribute to cardiovascular benefits beyond glycemic control.
  • To summarize current knowledge on SGLT2 inhibitors, DPP4 inhibitors, and GLP-1 RAs in managing diabetic dyslipidemia.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of studies investigating novel antidiabetic agents (SGLT2i, DPP4i, GLP-1 RAs).
  • Focus on effects on lipid profiles and cardiovascular outcomes.

Main Results:

  • Novel antidiabetic agents show significant improvements in cardiovascular outcomes.
  • These drugs demonstrate positive effects on lipid profiles, including ameliorating diabetic dyslipidemia.
  • Improved lipid profiles appear to contribute to the overall cardiovascular benefits observed.

Conclusions:

  • Novel antidiabetic medications offer a dual benefit in type-2 diabetes by improving glycemic control and lipid profiles.
  • Targeting diabetic dyslipidemia with these agents is crucial for reducing cardiovascular risk.
  • Further research supports the role of SGLT2i, DPP4i, and GLP-1 RAs in cardiovascular protection for diabetic patients.
Keywords:
cardiovascular diseasesdiabetesdipeptidyl peptidase-4 inhibitors (DPP4i)dyslipidemiaglucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs)sodium glucose transporter-2 inhibitors (SGLT2i)

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
210
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
706
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366